Effects of oral N-acetylcysteine on walking capaci... - BV FAPESP
Busca avançada
Ano de início
Entree
Conteúdo relacionado
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Effects of oral N-acetylcysteine on walking capacity, leg reactive hyperemia, and inflammatory and angiogenic mediators in patients with intermittent claudication

Texto completo
Autor(es):
da Silva, Jr., Natan D. [1] ; Roseguini, Bruno T. [2] ; Chehuen, Marcel [1] ; Fernandes, Tiago [1] ; Mota, Gloria F. [1] ; Martin, Priscila K. M. [3] ; Han, Sang W. [3] ; Forjaz, Claudia L. M. [1] ; Wolosker, Nelson [4] ; de Oliveira, Edilamar M. [1]
Número total de Autores: 10
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Sch Phys Educ & Sport, Dept Biodynam, BR-05508900 Sao Paulo, SP - Brazil
[2] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 - USA
[3] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo - Brazil
[4] Univ Sao Paulo, Sch Med, Dept Surg, Vasc & Endovasc Div, BR-05508900 Sao Paulo, SP - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY; v. 309, n. 5, p. H897-H905, SEP 1 2015.
Citações Web of Science: 7
Resumo

Increased oxidative stress and inflammation contribute to impaired walking capacity and endothelial dysfunction in patients with intermittent claudication (IC). The goal of the study was to determine the effects of oral treatment with the antioxidant N-acetylcysteine (NAC) on walking capacity, leg postocclusive reactive hyperemia, circulating levels of inflammatory mediators, and whole blood expression of angiogenic mediators in patients with IC. Following a double-blinded randomized crossover design, 10 patients with IC received NAC (1,800 mg/day for 4 days plus 2,700 mg before the experimental session) and placebo (PLA) before undergoing a graded treadmill exercise test. Leg postocclusive reactive hyperemia was assessed before and after the test. Blood samples were taken before and after NAC or PLA ingestions and 5 and 30 min after the exercise test for the analysis of circulating inflammatory and angiogenic markers. Although NAC increased the plasma ratio of reduced to oxidized glutathione, there were no differences between experimental sessions for walking tolerance and postocclusive reactive hyperemia. Plasma concentrations of soluble vascular cell adhesion protein-1, monocyte chemotactic protein-1, and endothelin-1 increased similarly following maximal exercise after PLA and NAC (P < 0.001). Whole blood expression of pro-angiogenic microRNA-126 increased after maximal exercise in the PLA session, but treatment with NAC prevented this response. Similarly, exercise-induced changes in whole blood expression of VEGF, endothelial nitric oxide synthase and phosphatidylinositol 3-kinase R2 were blunted after NAC. In conclusion, oral NAC does not increase walking tolerance or leg blood flow in patients with IC. In addition, oral NAC prevents maximal exercise-induced increase in the expression of circulating microRNA-126 and other angiogenic mediators in patients with IC. (AU)

Processo FAPESP: 13/05883-8 - Efeito da suplementação oral com N-acetilcisteína na capacidade de caminhada, capacidade vasodilatadora e marcadores de estresse oxidativo em pacientes com doença arterial periférica
Beneficiário:Nelson Wolosker
Modalidade de apoio: Auxílio à Pesquisa - Regular